81066-73-1

Usage

Type

Synthetic antifungal medication

Uses

Treats fungal infections such as athlete's foot, ringworm, and vaginal yeast infections

Mechanism of Action

Disrupts the cell membrane of fungi, leading to their death

Forms

Available as creams, powders, and solutions

Application

Topically to the affected area

Side Effects

Commonly causes skin irritation and itching

Classification

Broad-spectrum antifungal agent

Additional Usage

Often used in combination with other medications for severe or resistant infections

Upstream product

• 13816-33-6 p-Cyanocumen 
• 107-15-3 ethylenediamine 
• 53515-20-1 4-isopropyl-thiobenzamide 

Downstream Products

• 94672-32-9 4-isopropyl-cyclohexa-1,4-dienecarbaldehyde-(2,4-dinitro-phenylhydrazone) 
• 91341-59-2 p-mentha-1,4-dien-7-al semicarbazone 

Relevant academic research and scientific papers

Synthesis and pharmacological evaluation of imidazoline sites I1 and I2 selective ligands

Several series of 2-aryl or heterocyclic-imidazoline compounds have been prepared and evaluated in vitro as imidazoline sites (I1 and I2) and α-adrenergic (α1 and α2) receptor ligands. Their pKi values indicate that linkage of the imidazoline moiety at the 2-position with an aromatic substituent dramatically decreases α-adrenergic affinity. I1 sites are more accessible by phenyl imidazolines substituted by a methyl or a methoxy group at the ortho or meta position. Indeed, 2-(2′-methoxyphenyl)-imidazoline (17) is one of the best I1 ligands ever reported (pKi=8.53 and I1/I2>3388). On the other hand, I2 selectivity increases in the presence of a methyl group in the para position. The original compound, 2-(3′-fluoro-4′-tolyl)-imidazoline (31) is a new potent ligand for the I2 sites with high selectivity (pKi=8.53 and I2/I1>3388). Copyright